GlassScriptPhysician profile
Constance M Campanella
NPI 1093776833
$5,561.64
in general payments reported to CMS, 2019-2025
23 companies · $21.86 in 2025
The $21.86 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $1,810 · 2023: $1,620 · 2024: $1,040 · 2025: $21.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,483.84 | 2021-2024 | |
| Janssen Biotech, INC. | $694.54 | 2021-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $515.32 | 2021-2024 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $266.95 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.21 | 2021-2024 | Trulance, Xifaxan |
| Ironwood Pharmaceuticals, INC | $197.91 | 2021-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $189.79 | 2021-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $163.64 | 2021-2024 | Rebyota, Clenpiq |
| Ardelyx, INC. | $161.73 | 2023-2024 | Ibsrela |
| Pfizer INC. | $94.16 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $89.45 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.89 | 2023-2024 | Cyltezo |
| Daiichi Sankyo INC. | $61.24 | 2021-2023 | Injectafer |
| Braintree Laboratories, INC. | $59.44 | 2021-2023 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $49.39 | 2023-2024 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $46.27 | 2022 | |
| Amgen INC. | $43.28 | 2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $32.33 | 2022 | |
| Novo Nordisk INC | $24.22 | 2023 | Wegovy |
| Aimmune Therapeutics, INC. | $23.59 | 2024 | |
| Madrigal Pharmaceuticals | $21.86 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $21.49 | 2021 | |
| Genzyme Corporation | $17.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Campanella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.